OGT Signs Kreatech as Exclusive Distributor for
CytoSure™ in France
Deal provides OGT with an expanded customer base for its market-leading aCGH arrays
Oxford, UK – 18 March 2010. Oxford Gene Technology (OGT), the pioneer of microarraybased
technologies, has today announced that it has signed an exclusive distribution
agreement with Kreatech Diagnostics (Amsterdam, The Netherlands). The deal will enable
Kreatech Diagnostics to sell OGT’s CytoSure™ products throughout France, providing
customers with a comprehensive aCGH solution. Speaking ahead of the announcement,
Mike Evans, CEO of OGT said: “We are delighted to sign this distribution deal. Kreatech has
vast experience and a broad customer base in the genomic arena, and is therefore perfectly
positioned to market our CytoSure range in France.”
Commenting on the agreement, Harald Berninger, VP Sales and Marketing at Kreatech said:
“OGT’s CytoSure products are the only arrays with content specifically optimised for the
cytogenetic community. This advanced aCGH range represents the next step in cytogenetics
from our FISH probes. Through the distribution of OGT’s CytoSure we are now able to
package the arrays with our unique ULSTM labelling technology, offering our customers a
complete consumable solution.”
OGT’s CytoSure aCGH product line comprises a range of high quality arrays covering single
disorders through to syndrome focussed, genome wide coverage. The CytoSure arrays,
including the International Standard Cytogenomic Array (ISCA) Consortium-approved series,
meet the resolution, multiplexing and budget requirements of both cytogeneticists and
molecular biologists. Furthermore, each CytoSure array comes with CytoSure Interpret
Software for effortless translation of data into meaningful results. The software allows fast
and standardised data analysis through customisable workflows, automatic aberration
identification, and comprehensive contextual input via integration with public aberration
databases (e.g. Decipher and the Database of Genomic Variants) and the facility to build
and share institutional databases.
Notes for editors:
About Oxford Gene Technology:
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide. The OGT CytoSure™ cytogenetics array, labelling and interpretation software products provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomics in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.
CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.